Please assess the completion status of the following clinical trial:

Trial Title: S-1/Oxaliplatin for High Risk Patients Who Underwent Gastrectomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who voluntarily provide written informed consent prior to entering into this study~* Newly definitely diagnosed with primary gastric or gastroesophageal junction adenocarcinoma histologically~* Patients who underwent radical resection with wide lymph node dissection~* TNM stage (6th AJCC) of IIIB or IV on post-operative staging~* Patients who can be randomized within 6 weeks after surgery~Exclusion Criteria:~* Aged \< 20 years or ≥ 76 years~* Eastern Cooperative Oncology Group (ECOG) performance status \>2~* Patients who underwent surgery for neoplasm in stomach in the past~* History of malignant disease The following cases can be included in this study - adequately treated basal cell or squamous cell skin cancer, cervical carcinoma in situ~* Gastric or gastroesophageal junction adenocarcinoma with distant metastasis (M1) including distant lymph node (behind the pancreas, along the aorta, portal vein, behind the peritoneum, mesenteric lymph node)~* Residual cancer on post-operative staging (R1 and R2 resection)~* Patients who received adjuvant chemotherapy, or neoadjuvant chemotherapy and/or radiotherapy and/or immunotherapy in the past for treatment of gastric cancer~* Any of the following within 6 months prior to the study recruitment: Myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass, NYHA class III or IV congestive heart failure, stroke or transient ischemic attack, serious cardiac arrhythmia requiring treatment~* Patients of childbearing potential who do not agree to use generally accepted effective method of birth control during the study treatment period and for at least 6 months after the end of study treatment~* Pregnant women, breastfeeding women, or women of childbearing potential whose pregnancy test result is positive•~* History of hypersensitivity to the investigational products (S1 and Oxaliplatin)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- S-1/Oxaliplatin (Type: EXPERIMENTAL): S-1 80 mg/m²/day from day 1 to day 14, every 21 days, for 12 months; Oxaliplatin 130 mg/m² for day 1, every 21 days, for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).